Rucaparib Recruiting Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03533946Rucaparib in Nonmetastatic prOstAte With BRCAness
NCT03338790An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer